Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : DIACC3010,Tamoxifen Citrate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DIACC3010 was well tolerated in monotherapy and potential biomarkers of pharmacological activity were seen in peripheral blood mononuclear cells and tumor tissues.
Product Name : DIACC3010
Product Type : Small molecule
Upfront Cash : Not Applicable
April 06, 2023
Lead Product(s) : DIACC3010,Tamoxifen Citrate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : DIACC2010
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DIACC2010 is a selective inhibitor of kinesin KIF20A, a novel oncology target, involved in the functions of the Golgi apparatus and the control of cell division. DIACC2010 has shown potent preclinical antitumor efficacy in aggressive models of AML and so...
Product Name : DIACC2010
Product Type : Small molecule
Upfront Cash : Not Applicable
January 05, 2023
Lead Product(s) : DIACC2010
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable